Arvinas (ARVN) News Today $18.05 +0.47 (+2.67%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Arvinas Holding Company Positioned for Growth with Strategic Advancements and Promising Clinical DevelopmentsJanuary 16, 2025 | markets.businessinsider.comArvinas (NASDAQ:ARVN) Sets New 12-Month Low - Should You Sell?Arvinas (NASDAQ:ARVN) Hits New 12-Month Low - Should You Sell?January 13, 2025 | marketbeat.comArvinas Holding Company: Strategic Pipeline Advancements and Promising Clinical Developments Justify Buy RatingJanuary 11, 2025 | markets.businessinsider.comArvinas updates milestones for 2025January 10, 2025 | markets.businessinsider.comArvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate UpdateJanuary 10, 2025 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVNJanuary 8, 2025 | prnewswire.comJPMorgan Chase & Co. Increases Position in Arvinas, Inc. (NASDAQ:ARVN)JPMorgan Chase & Co. lifted its holdings in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 18.7% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 2,329,303 shares of the company's stock after purchasing an additional 367,343 shares duriJanuary 5, 2025 | marketbeat.comArvinas (NASDAQ:ARVN) Stock Price Up 9.2% - Here's What HappenedArvinas (NASDAQ:ARVN) Stock Price Up 9.2% - What's Next?January 3, 2025 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVNJanuary 2, 2025 | prnewswire.comArvinas, Inc. (NASDAQ:ARVN) Short Interest Up 6.5% in DecemberArvinas, Inc. (NASDAQ:ARVN - Get Free Report) saw a large increase in short interest during the month of December. As of December 15th, there was short interest totalling 9,610,000 shares, an increase of 6.5% from the November 30th total of 9,020,000 shares. Based on an average daily volume of 719,200 shares, the days-to-cover ratio is currently 13.4 days.December 31, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVNDecember 27, 2024 | prnewswire.comArvinas, Inc. (NASDAQ:ARVN) Given Average Rating of "Moderate Buy" by BrokeragesArvinas, Inc. (NASDAQ:ARVN - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the fifteen ratings firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold rating and fourteen have issued a buy rating on the company. TheDecember 27, 2024 | marketbeat.comArvinas (NASDAQ:ARVN) Shares Down 3.3% - Should You Sell?Arvinas (NASDAQ:ARVN) Stock Price Down 3.3% - Time to Sell?December 26, 2024 | marketbeat.comArvinas' Vepdegestrant: Why The Data May Not Hold UpDecember 25, 2024 | seekingalpha.comBarclays PLC Purchases 80,984 Shares of Arvinas, Inc. (NASDAQ:ARVN)Barclays PLC raised its holdings in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 198.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 121,699 shares of the company's stock after purchasing an adDecember 25, 2024 | marketbeat.comArvinas, Inc. (NASDAQ:ARVN) Stake Lowered by State Street CorpState Street Corp trimmed its stake in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 3.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,643,727 shares of the company's stock after selling 55,961 shares during theDecember 21, 2024 | marketbeat.comArvinas (NASDAQ:ARVN) Stock Price Down 6.2% - Here's What HappenedArvinas (NASDAQ:ARVN) Shares Down 6.2% - Here's What HappenedDecember 19, 2024 | marketbeat.comArvinas (NASDAQ:ARVN) Sets New 12-Month Low - What's Next?Arvinas (NASDAQ:ARVN) Hits New 1-Year Low - Should You Sell?December 18, 2024 | marketbeat.comBuy Rating for Arvinas Holding Company Driven by Vepdeg’s Promising Potential and Market OpportunityDecember 16, 2024 | markets.businessinsider.comArvinas, Inc. (NASDAQ:ARVN) Short Interest Up 5.6% in NovemberArvinas, Inc. (NASDAQ:ARVN - Get Free Report) was the recipient of a large growth in short interest in November. As of November 30th, there was short interest totalling 9,020,000 shares, a growth of 5.6% from the November 15th total of 8,540,000 shares. Based on an average daily trading volume, of 577,200 shares, the days-to-cover ratio is presently 15.6 days.December 16, 2024 | marketbeat.comBarclays Keeps Their Buy Rating on Arvinas Holding Company (ARVN)December 14, 2024 | markets.businessinsider.comArvinas, Inc. (NASDAQ:ARVN) Holdings Lowered by BNP Paribas Financial MarketsBNP Paribas Financial Markets trimmed its stake in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 55.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 37,349 shares of the company's stock after selDecember 12, 2024 | marketbeat.comPromising Potential and Strong Efficacy of Arvinas Holding’s Vepdeg+Abema Combination Drive Buy RatingDecember 11, 2024 | markets.businessinsider.comDemystifying Arvinas: Insights From 5 Analyst ReviewsDecember 11, 2024 | benzinga.comArvinas Holding Company (ARVN) Receives a Buy from Evercore ISIDecember 11, 2024 | markets.businessinsider.comArvinas (NASDAQ:ARVN) Receives Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $87.00 target price on shares of Arvinas in a research report on Wednesday.December 11, 2024 | marketbeat.comArvinas, Pfizer Report Positive Data From Phase 1b Study Of Vepdegestrant Combination TherapyDecember 10, 2024 | markets.businessinsider.comArvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer SymposiumDecember 10, 2024 | globenewswire.comArvinas (NASDAQ:ARVN) Coverage Initiated by Analysts at BTIG ResearchBTIG Research initiated coverage on Arvinas in a report on Tuesday. They set a "buy" rating and a $69.00 target price for the company.December 10, 2024 | marketbeat.comVerition Fund Management LLC Cuts Stock Position in Arvinas, Inc. (NASDAQ:ARVN)Verition Fund Management LLC decreased its position in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 57.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,631 shares of the compDecember 9, 2024 | marketbeat.comFmr LLC Grows Stock Holdings in Arvinas, Inc. (NASDAQ:ARVN)Fmr LLC lifted its position in Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 7.6% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,883,604 shares of the company's stock after purchasing an additional 204,317 shDecember 7, 2024 | marketbeat.comRTW Investments LP Trims Stock Position in Arvinas, Inc. (NASDAQ:ARVN)RTW Investments LP lowered its stake in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 6.3% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 2,782,329 shares of the company's stock after selling 185,568 shares during the period. RTW Investments LP oDecember 5, 2024 | marketbeat.comWhy Is Arvinas, Inc. (ARVN) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?December 4, 2024 | msn.comParkman Healthcare Partners LLC Sells 28,978 Shares of Arvinas, Inc. (NASDAQ:ARVN)Parkman Healthcare Partners LLC cut its holdings in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 23.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 96,183 shares of the compaDecember 4, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVNDecember 3, 2024 | prnewswire.comBaker BROS. Advisors LP Takes Position in Arvinas, Inc. (NASDAQ:ARVN)Baker BROS. Advisors LP acquired a new position in Arvinas, Inc. (NASDAQ:ARVN - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 405,576 shares of the company's stock, valuDecember 2, 2024 | marketbeat.comArvinas, Inc. (NASDAQ:ARVN) Receives Average Recommendation of "Moderate Buy" from BrokeragesArvinas, Inc. (NASDAQ:ARVN - Get Free Report) has earned a consensus rating of "Moderate Buy" from the fourteen research firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and thirteen have assigned a buDecember 2, 2024 | marketbeat.comArvinas, Inc. (NASDAQ:ARVN) Shares Bought by Wasatch Advisors LPWasatch Advisors LP lifted its stake in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 58.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 435,943 shares of the company's stock after buying an additional 160,510 shareDecember 1, 2024 | marketbeat.comBraidwell LP Boosts Stock Position in Arvinas, Inc. (NASDAQ:ARVN)Braidwell LP boosted its holdings in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 148.3% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,284,472 shares of the company's stock after acquiring an adNovember 29, 2024 | marketbeat.comArvinas to Present at Piper Sandler 36th Annual Healthcare ConferenceNovember 27, 2024 | globenewswire.comPositive Outlook for Arvinas Due to Promising Safety Data and Upcoming DevelopmentsNovember 26, 2024 | markets.businessinsider.comArvinas Holding Co.: Promising Advances in Breast Cancer Treatment Drive Buy RatingNovember 26, 2024 | markets.businessinsider.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVNNovember 25, 2024 | prnewswire.comArvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer SymposiumNovember 25, 2024 | globenewswire.comAlgert Global LLC Purchases 123,613 Shares of Arvinas, Inc. (NASDAQ:ARVN)Algert Global LLC grew its position in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 278.1% in the third quarter, according to its most recent filing with the SEC. The fund owned 168,061 shares of the company's stock after acquiring an additional 123,613 shares during the quarter. Algert GNovember 25, 2024 | marketbeat.comLeerink Partnrs Issues Negative Outlook for Arvinas EarningsArvinas, Inc. (NASDAQ:ARVN - Free Report) - Leerink Partnrs cut their FY2025 earnings per share estimates for Arvinas in a report issued on Tuesday, November 19th. Leerink Partnrs analyst A. Berens now anticipates that the company will earn ($2.98) per share for the year, down from their previousNovember 22, 2024 | marketbeat.comArvinas Holding’s VERITAC-2 Trial Progress Drives Buy Rating Despite Adjusted Price TargetNovember 22, 2024 | markets.businessinsider.comArvinas price target lowered to $88 from $90 at BMO CapitalNovember 20, 2024 | markets.businessinsider.comStephens & Co. Initiates Coverage of Arvinas (ARVN) with Overweight RecommendationNovember 19, 2024 | msn.comArvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To ExplodeNovember 19, 2024 | insidermonkey.com Get Arvinas News Delivered to You Automatically Sign up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter. Email Address ARVN Media Mentions By Week ARVN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARVN News Sentiment▼0.140.44▲Average Medical News Sentiment ARVN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARVN Articles This Week▼15▲ARVN Articles Average Week Get Arvinas News Delivered to You Automatically Sign up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TGTX News Today AXSM News Today KRYS News Today VRNA News Today OGN News Today SRRK News Today ALVO News Today BHVN News Today ADMA News Today APLS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARVN) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTop Picks for Trump’s Pro-Crypto AmericaThe Crypto ETF Windfall: 27 Experts Tell All (Free) Don't miss your chance to see exactly what crypto's eli...Crypto 101 Media | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arvinas, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arvinas With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARVN Stock Alerts